EVE Health Group (ASX: EVE) Announces Telehealth Partnership to Support Product Launches

In a recent investor update, EVE Health Group Limited (ASX: EVE) has entered into a Patient Support Telehealth Services Agreement with hubMed Pty Ltd, a leading Australian telehealth provider. The agreement establishes a nationwide programme designed to enhance the safety, quality and continuity of care for patients prescribed EVE’s therapeutic products, including Dyspro™ for dysmenorrhoea and Libbo™ for erectile dysfunction. This EVE Health hubMed Telehealth partnership addresses critical gaps in women’s and men’s health, where conditions often go under-diagnosed and under-managed due to stigma, delayed help-seeking, and inconsistent follow-up.

The programme connects patients with Registered Nurses who provide regular touchpoints to support adherence, triage concerns, and communicate with treating practitioners when clinically necessary. This operational development strengthens the commercial foundation for both products during crucial launch phases. Dyspro has recently launched, whilst Libbo’s commercial release is upcoming. For investors tracking EVE’s progress, this partnership represents a strategic infrastructure investment that could materially impact product adoption rates and prescription continuity.

EVE Health Company Snapshot (ASX: EVE)

• Market Capitalisation: [Insert Data]
• Shares on Issue: [Insert Data]
• Cash at Bank: [Insert Data]

Why Has EVE Health Partnered with hubMed for Telehealth Services?

The partnership between EVE Health and hubMed creates a structured clinical support framework that complements traditional medical care rather than replacing it. Registered Nurses conduct scheduled follow-up consultations accessible via telehealth, creating a communication bridge between patients and their treating practitioners. This approach addresses a known market friction point that historically limits treatment uptake for both women’s and men’s health conditions.

Improving continuity of care is critical in both women’s and men’s health, where conditions often go under-diagnosed and under-managed. Many patients require structured follow-up to support adherence, address symptoms early and reinforce clinical guidance in a timely manner. Furthermore, the EVE Health hubMed Telehealth partnership operates under a clinical governance framework ensuring quality standards are maintained throughout the patient journey.

The clinical team’s responsibilities include reinforcing safe medication use and proper dosing, triaging patient concerns within nursing scope, and escalating issues to prescribers when clinically necessary. This structured approach supports adherence, which is critical for treatment efficacy and directly impacts prescription continuation rates. In addition, patients can access consultations from home or workplace, reducing barriers to follow-up care that often affect treatment outcomes.

“Women’s and men’s health conditions are often overlooked, and patients benefit greatly from reliable follow-up and trusted clinical support. This partnership strengthens our ability to provide that support. hubMed has a strong clinical governance framework and a model that helps patients stay informed, confident and connected to their treating practitioners. It is an important step in delivering better outcomes for patients who are prescribed our therapies,” said Damian Wood, Chief Executive Officer.

“Our Registered Nurses have significant experience supporting patients in areas where continuity of care is especially important. We are pleased to partner with EVE on a programme that prioritises patient wellbeing, safety and communication with prescribers. This model helps ensure that patients feel supported throughout their treatment journey,” said Jessica Stewart, Managing Director at hubMed.

Key Benefits of the EVE Health hubMed Telehealth Partnership:

• Accessible telehealth consultations delivered by independent clinicians
• Proactive nurse-led check-ins at key treatment milestones
• Direct communication pathway to treating physicians
• Ongoing adherence reinforcement and symptom monitoring
• Reduced barriers to treatment continuity

The model creates regular touchpoints that allow early identification of concerns before they become significant issues requiring emergency intervention. Documentation and communication protocols ensure treating physicians remain informed of patient progress and any clinical concerns that arise between traditional appointments.

How Does the hubMed Telehealth Model Support Dyspro and Libbo Patients?

The EVE Health hubMed Telehealth partnership provides structured clinical support through scheduled follow-up consultations that address common treatment challenges. Registered Nurses deliver these services under a clinical governance framework, ensuring quality standards whilst preserving the treating practitioner’s central role in patient care. This approach demonstrates EVE’s commitment to real-world outcomes beyond product development.

The programme operates through accessible telehealth consultations that eliminate geographical barriers and reduce time constraints. Patients prescribed either Dyspro for dysmenorrhoea or Libbo for erectile dysfunction receive scheduled contact from qualified nursing staff who can reinforce clinical guidance, monitor adherence patterns, and identify potential concerns early in the treatment journey. This proactive model contrasts sharply with traditional care pathways that rely solely on patient-initiated contact between scheduled appointments.

For Dyspro patients managing dysmenorrhoea, the programme provides scheduled Registered Nurse follow-up to help ensure adherence, reinforce correct use and provide early support for symptom-related concerns within scope. Similarly, men prescribed Libbo will have access to structured Registered Nurse contact to support correct use, triage non-urgent issues within scope and escalate clinical matters to prescribers when appropriate. This consistency across both therapeutic areas creates operational efficiencies whilst maintaining clinical focus.

The telehealth infrastructure allows rapid deployment across both therapeutic areas whilst preserving capital for other commercial activities. hubMed’s established platform and experienced nursing staff enable nationwide coverage without requiring EVE to build internal infrastructure. This approach accelerates time to market for patient support services that can differentiate EVE’s products from alternatives lacking structured follow-up programmes.

What Is the Market Size for Dysmenorrhoea and Endometriosis Treatments?

Dysmenorrhoea affects the majority of women of reproductive age, creating a substantial market opportunity for effective therapeutic solutions. A recent Australian study found that 77% of women aged 18 to 44 experience disruptive menstrual symptoms, with almost half reporting missed days of work or study. The economic burden of menstrual symptoms in Australia is estimated at approximately $14.2 billion (AUD) per year, highlighting the significant societal impact of inadequately managed conditions.

More severe cases may be associated with endometriosis, which affects up to 10% of reproductive-age women. The annual cost per woman with chronic pelvic pain can exceed $16,000 (USD), with lost productivity accounting for 75-84% of the total burden. These statistics underscore the scale of unmet need that Dyspro has been developed to address under the supervision of authorised prescribers.

The combination of high prevalence, significant economic impact, and substantial quality-of-life burden creates favourable market conditions for innovative therapeutic approaches. However, stigma and delayed help-seeking behaviour historically limit treatment uptake, which is precisely where the telehealth programme adds commercial value. By reducing barriers to care continuity, structured patient support can improve real-world treatment outcomes, which directly impacts product adoption rates and prescription continuation.

What Is the Market Opportunity for Erectile Dysfunction Treatments?

Erectile dysfunction affects one in five men over the age of 18 and up to 40% of men over 40, representing a substantial market opportunity in men’s health. The condition impacts wellbeing, confidence and relationships, yet remains under-treated due to stigma, delayed help-seeking and inconsistent follow-up. These market friction points create opportunities for therapeutic solutions paired with structured patient support programmes.

Libbo, EVE’s oral dissolving film for erectile dysfunction, has been designed to offer prescribers a modern dosage form that may support better adherence and patient acceptance. The oral dissolving film format provides rapid onset and improved convenience compared to traditional tablet formulations, which may enhance patient adherence. The addition of the telehealth service is intended to further support patients, potentially improving treatment success and long-term prescription continuity.

This latest ASX announcement confirms that the EVE Health hubMed Telehealth partnership is a key component of the commercialisation strategy for both Dyspro and Libbo. By integrating clinical product innovation with modern patient support infrastructure, EVE Health aims to capture a greater share of these significant markets.

Want more ASX news?

Looking to stay ahead of major developments in ASX healthcare and biotechnology companies? Subscribe to StockWire X’s free Big News Blasts and join over 20,000 investors receiving instant email alerts on significant announcements, including strategic partnerships like EVE Health’s telehealth innovation. Each alert comes with comprehensive analysis, ensuring you access only the most important market-moving news without the noise. Join today to receive expert insights delivered directly to your inbox.